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O-GlycansGalectin-3 has been reported to induce apoptosis of Jurkat cells through binding receptors such as
CD45. CD45RABC is heavily O-glycosylated and N-glycosylated, while CD45RO is only N-glycosylated.
In this study, no apoptosis induced by galectin-3 was detected in CD45RO-transfected cells, whereas
apoptosis of CD45RABC-transfected cells was observed, implying that O-glycans on CD45 might play
roles in galectin-3-induced apoptosis. O-Glycosylation inhibition assay further suggests the role of
O-glycans on CD45 in regulation of galectin-3-induced apoptosis. We also found that deglycosylation
at N327 of CD45RO resulted in increased binding to galectin-3 without affecting apoptosis, while
deglycosylation at N36 or N109 of CD45RO enhanced galectin-3-induced apoptosis. These data dem-
onstrate that galectin-3-induced apoptosis of Jurkat cells is regulated by both O-glycans and N-gly-
cans on CD45.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction cans of cell surface glycoproteins. The identiﬁed receptors for bothGalectin is a family of soluble lectins that binds b-galactoside-
containing glycans and forms supramolecular structures on cell
surface. Galectins are characterized by a highly conserved carbohy-
drate recognition domain (CRD) with a speciﬁcity of binding to car-
bohydrate and have a structural folding in common [1,2]. To date,
ﬁfteen galectins have been identiﬁed in mammals and they are
thought to mediate diverse biological processes involved in the
regulation of the innate and the adaptive immune responses, such
as cell activation, differentiation, cytokine secretion, and apoptosis
[3,4]. Among members of the galectin family, galectin-1 and galec-
tin-3 are the most ubiquitously expressed and the most exten-
sively studied [5–8]. Galectin-1 and galectin-3 have been shown
to induce cell death by binding the b-galactoside-containing gly-galectin-1 and galectin-3 are CD29, CD43, and CD45, whereas only
galectin-3 binds CD71, and only galectin-1 binds CD7 and CD2 [9].
CD45 is a type I glycoprotein, containing a single transmem-
brane domain. Its cytoplasmic domain consists of tandem protein
tyrosine phosphatase (PTPase) domains and a C-terminal tail of
approximately 80 amino acids [10]. The extracellular domain prox-
imal to the cell membrane covers three tandem ﬁbronectin type III
domains which are heavily N-glycosylated. The N-terminal of the
extracellular part can include 1, 2 or 3 additional domains termed
A, B, and C. These contain numerous serine and threonine residues
with core 1 or core 2 O-glycosylation. Between the C- and N-termi-
nal domains, a cysteine-rich region is present [11,12]. At the cell
surface, CD45 can exist as multiple isoforms resulting from alterna-
tive RNA splicing of exons 4, 5, and 6 which code for A, B, and C do-
mains in the extracellular domain. CD45RABC contains all the
ﬁbronectin type III domains, the cysteine-rich region, and A, B
and C domains. CD45RO lacks the three A, B and C domains and
has only the ﬁbronectin type III domains and the cysteine-rich re-
gion [12]. While the N-glycosylated region of the extracellular do-
main is conserved, the main variation exists in the length of the
O-glycosylated region (A, B, or C domains). In addition, the number
of O-glycans on CD45 can vary signiﬁcantly among different iso-
forms and the number of N-glycans on CD45RO can vary by differ-
ent lymphocyte subsets at distinct developmental stages [13–16].
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tively regulate galectin-1-induced cell death depending on cell
types. Both N-glycans and O-glycans are reported to be involved
in CD45-mediated apoptosis induced by galectin-1 [11,14]. How-
ever, CD45 expression is not absolutely required for galectin-1-in-
duced T cell death and CD45RO expression even exhibited
reduced susceptibility to galectin-1-induced apoptosis in murine
BW5147, BW5147(Rev1.1), and T200 cell lines [17].
CD45 involvementhas alsobeen reported ingalectin-3-mediated
cell death. Stillman et al. observed that galectin-3 induced apoptosis
of CD45+ Jurkat cells, whereas cells lacking CD45were not suscepti-
ble to galectin-3. Interestingly, CD45RABC transfection in these
CD45 cells restored CD45 expression and more importantly, sus-
ceptibility to galectin-3 [9]. Clark et al. reported the importance of
speciﬁc glycosylation of CD45 in the regulation of galectin-3-medi-
ated signaling. They found that galectin-3 could bind to CD45 on dif-
fuse large B-cell lymphoma cells, regulating susceptibility to cell
death modiﬁed by C2GnT-1 glycosyltransferase [18]. However, the
roles of O-glycans and/or N-glycans on CD45 in cell death induced
by galectin-3 remain unknown. Using CD45RABC containing both
O-glycans and N-glycans and CD45RO containing N-glycans only,
the regulation of galectin-3-induced cell death was investigated.
The role of O-glycans and/or N-glycans on CD45 in the regulation
of cell deathwas examined by transfection of CD45RABC or CD45RO
with individual removal of N-glycosylation sites into CD45 J45.01
cells. We observed galectin-3-induced cell death in CD45RABC-
J45.01 cells but not in CD45RO-J45.01 cells. Moreover, death of
CD45RABC-J45.01 cells induced by galectin-3 could be modiﬁed by
O-glycosylation inhibitor Benzyl-GalNAc, demonstrating roles
playedbyO-glycans onCD45 in the regulationof galectin-3-induced
Jurkat cell death. Meanwhile, we also found that site-speciﬁc deple-
tion of N-glycans in CD45RO cells affected galectin-3-binding and
the initiation of apoptosis, indicating that galectin-3-induced Jurkat
cell death was also regulated by N-glycans on CD45.Table 1
Primers used for site-directed mutagenesis of CD45RO.
N36Q 50-GGTTGTTTCAGAGGCCTGAAGGTAGGCATCAG-30
50-CTGATGCCTACCTTCAGGCCTCTGAAACAACC-30
N71Q 50-GATGAAAAATATGCACAGATCACTGTGGATTAC-30
50-GTAATCCACAGTGATCTGTGCATATTTTTCATC-30
N99Q 50-GTTTGTGCAAGTATTCTGTCCACATTCCACATTC-30
50-GAATGTGGAATGTGGACAGAATACTTGCACAAAC-30
N109Q 50-CATTTTTACATTCTGTAAGCTGATGCACCTCATTG-30
50-CAATGAGGTGCATCAGCTTACAGAATGTAAAAATG-30
N115Q 50-GGAAACAGACGCCTGTTTACATTCTGTAAG-30
50-CTTACAGAATGTAAACAGGCGTCTGTTTCC-30
N174Q 50-CTGAAATCTGTAGGTAATCTGCTGTGTATCACAAG-30
50-CTTGTGATACACAGCAGATTACCTACAGATTTCAG-30
N217Q 50-GTTTTAATAATTTTACTTGCCTGAGTAAACTTGTGG-30
50-CCACAAGTTTACTCAGGCAAGTAAAATTATTAAAAC-30
N258Q 50-CAGAGGGTAAACTGATGAAATGATCTTTG-30
50-CAA AGATCATTTCATCAGTTTACCCTCTG-30
N307Q 50-GGTTGTTTCAGAGGCCTGAAGGTAGGCATCAG-30
50-CTGATGCCTACCTTCAGGCCTCTGAAACAACC-30
N327Q 50-GGAGACAGTCATCTGCCAGACCTGGCTTGG-30
50-CCAAGCCAGGTCTGGCAGATGACTGTCTCC-30
N368Q 50-GCAATTCTTATGCGACTCCTGTCTAACCAGAGTATTTC-30
50-GAAATACTCTGGTTAGACAGGAGTCGCATAAGAATTGC-302. Materials and methods
2.1. Cell culture and transfection
The human leukemia cell line, Jurkat (Clone E6-1), and the
CD45-deﬁcient cell line, J45.01, were obtained from the American
Type Culture Collection. Cells were maintained in RPMI 1640 med-
ium containing 100 U of penicillin per ml and 0.1 mg of streptomy-
cin per ml and 10% fetal bovine serum (FBS) in 5% CO2 at 37 C. HEK
293T cells were grown in DMEM containing 10% FBS and antibiot-
ics at 37 C in 5% CO2. J45.01 cells stably expressing WT-CD45RO,
CD45RABC, and mutated-CD45RO were established by lentiviral
transduction and evaluated for receptor expression by ﬂow cytom-
etry. cDNA of WT-CD45RO, CD45RABC or mutated-CD45RO was in-
serted into lentiviral vector pWPXL between MluI and SpeI.
Lentiviruses produced in 293T cells by co-transfection of pWPXL-
CD45, packaging vector psPAX2 and envelope vector pMD2.G were
used to infect J45.01 cells. Target cells were infected with superna-
tants from packing cells supplemented with 10 lg/ml polybrene.
2.2. Reagents
Recombinant human galectin-3 was obtained from R&D Sys-
tems (Minneapolis, MN). Benzyl-GalNAc was purchased from Sig-
ma–Aldrich (St. Louis, MO). APC-labeled CD43, PE-labeled CD29,
FITC-labeled CD71, PE-labeled CD45RO mAb and FITC-labeled
CD45RA mAb were obtained from BioLegend (San Diego, CA).
Anti-CD45 antibody for Western blot was obtained from Abcam
(Cambridge, UK). HRP-labeled goat anti-rabbit IgG polyclonal anti-
body was purchased from Zhongshan Biotechnology Co (Beijing,China). PerCP-labeled CD3 and PE-labeled mouse anti-human
galectin-3 Set (B2C10) were purchased from BD Pharmingen (San
Jose, CA).
2.3. Site-directed mutagenesis
Site-directed polymerase chain reaction (PCR) mutagenesis was
used for mutation of Asp-X-Ser/Thr to Glu-X-Ser/Thr in CD45RO
cDNA. The template cDNA of CD45RO and CD45RABC were pur-
chased from OriGene (Rockville, MD). PCR was performed with
CD45 upstream primer 50-CGA CGC GTA CCA TGT ATT TGT GGC
TTA AAC TCT-30 and downstream primers with a stop codon 50-
GGA CTA GTC TAT GAA CCT TGA TTT AAA GCT GGA-30. For each site,
two reactions with primers overlapping the desired amino acid ex-
change were performed. The two products were annealed and
ampliﬁed with the ﬂanking CD45RO primers (Table 1). The ﬁnal
products were individually inserted into MluI/SpeI site of pWPXL
vector. Successful mutagenesis was conﬁrmed by sequencing.
2.4. Western blot
Cell were lysed with ice-cold lysis buffer, run on 6% SDS–PAGE,
and then transferred onto a nitrocellulose membrane. After block-
ing with 5% skimmed milk for 1 h at room temperature, mem-
branes were incubated with rabbit anti-human CD45 antibody
overnight at 4 C. Then, membranes were washed with PBST and
incubated with HRP-labeled goat anti-rabbit antibody. Membranes
were visualized by Super Signal West Pico chemiluminescent sub-
strate (Pierce, Rockford, IL).
2.5. RT-PCR
Total RNA was extracted using RNAeasy Mini kit (Qiagen,
Valencia, CA). Reverse transcriptase-polymerase chain reaction
(RT-PCR) was performed on 1 lg RNA using Super Script One-Step
RT-PCR Kit (Invitrogen, Carlsbad, CA). PCR was performed to ampli-
fy CD45RO and CD45RABC.
2.6. Flow cytometry
Cells were incubated with APC-labeled CD43, PE-labeled CD29,
FITC-labeled CD71, PerCP-labeled CD3, PE-labeled CD45RO or FITC-
labeled CD45RA, and then evaluated by ﬂow cytometry (FACS Aria;
BD, CA). For galectin-3 binding assay on cell surface, 180 nM
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The cell suspension was incubated at 4 C for 1 h. After washing,
cells were incubated with PE-labeled mouse anti-human galec-
tin-3 Set according to the protocol of the product. b-Lactose
(0.1 M) was used for inhibition assay of galectin-3 binding. Galec-
tin-3 binding was then detected upon ﬂow cytometry and analyzed
with FCS Express software. Quantiﬁcation of galectin-3 binding to
CD45RO was expressed as that described [19,20]. The relative
galectin-3 binding was calculated by dividing galectin-3 MFI
(mean ﬂuorescence intensity) with CD45RO MFI.
2.7. Morphology and apoptosis assay
Cell morphology in culturewas examined under amicroscopy as
described previously [2]. Cells (5  105) were incubated at 37 C in
phosphate buffered saline (PBS) with or without 3 lM galectin-3
for 5.5 h. Apoptosis at both early- and late-stage was measured
after indicated treatment using PE-labeled Annexin-V and PerCP-
labeled 7-AAD. For O-glycosylation inhibition assay, cells were pre-
treated with 1 mM Benzyl-GalNAc for 24 h and then exposed to
3 lM galectin-3 for 5.5 h. All samples were assayed in triplicate
and analyzed by ﬂow cytometry (FACS Aria; BD, CA). The percent-
age of apoptotic cells was determined with the following formula
as previously described [9]: ((percent Annexin-V 7-AAD cells in
control-treated sample) – (percent Annexin-V 7-AAD cells in
galectin-3-treated sample))/(percent Annexin-V 7-AAD cells
in control-treated sample).
2.8. Detection of mitochondrial membrane potential
Mitochondrial membrane potential was evaluated by cationic
dye JC-1 according to the protocol of the product (BD Pharmingen,
San Jose, CA). Galectin-3-treated (3 lM, 5.5 h), FasL-treated
(200 ng/ml, 18 h) or untreated cells (1  106) were incubated with
JC-1 (10 lg/ml) for 15 min at 37 C in dark and analyzed by ﬂow
cytometry.
2.9. TUNEL assay
Cellular DNA fragmentation was assessed using the TUNEL (ter-
minal deoxynucleotidyl transferase dUTP nick end labeling) reac-
tion (APO-BRDU™ Kit, BD Pharmingen, San Jose, CA). 1  106
cells were incubated with Br-dUTP for 60 min at 37 C followed
by incubation with FITC-labeled anti-BrdU mAb for 30 min at room
temperature in dark and analyzed by ﬂow cytometry.
2.10. Statistical analysis
Data were represented as mean ± S.E.M. The unpaired two-
tailed t-test was performed to determine statistical signiﬁcance be-
tween the groups. p < 0.05 was considered signiﬁcant. All data
were analyzed using GraphPad Prism software.3. Results
3.1. Role of CD45 in apoptosis induction of Jurkat cells by galectin-3
The J45.01 cell line is a CD45 deﬁcient variant of the E6-1 clone of
Jurkat cells. Western blotting demonstrated the expression of CD45
on JE6-1 cells and its absence on J45.01 cells (Fig. 1A). Although
galectin-3 induced aggregation of both J45.01 and JE6-1 cells
(Fig. 1B), galectin-3 was able to induce apoptosis of 40.08 ± 1.80%
of JE6-1 cells, but only 7.39 ± 1.24% of J45.01 cells (Fig. 1C), indicat-
ing that apoptosis induction by galectin-3 was associated with the
expression of CD45 on cells. Since phosphatidylserine (PS) stainedby Annexin-V could be transiently exposed but not mean cell death,
JC-1 and TUNEL assays were used to conﬁrm apoptotic process. The
loss ofmitochondrialmembranepotential, a usual hallmarkof apop-
tosis, was explored using the cationic dye JC-1. In non-apoptotic
cells, JC-1 accumulates as aggregates in mitochondria, resulting in
red ﬂuorescence (FL-2). In apoptotic cells where mitochondrial
membrane potential was collapsed, JC-1 exists in the cytosol as a
green ﬂuorescence (FL-1). Fig. 1D shows that galectin-3 induces
the intrinsic pathway of apoptosis of JE6-1 cells (56.07 ± 7.62% vs
22.86 ± 3.60% compared to untreated control) where mitochondria
is a key player, but not of J45.01 cells (21.59 ± 2.90% vs
23.63 ± 2.38% compared to untreated control). In addition, TUNEL
assay was also used as a usual method to highlight apoptosis by
detecting DNA fragmentation. Fig. 1E shows increase of BrdU in
galectin-3-treated JE6-1 cells but not in galectin-3-treated J45.01
cells, whereas FasL-induced cell death was found in both JE6-1 cells
and J45.01 cells. All these data demonstrate that galectin-3 induces
the apoptosis of JE6-1 cells, but not that of J45.01 cells, which indi-
cates the role of CD45 in apoptosis induction of JE6-1 cells by galec-
tin-3.
3.2. Regulation of galectin-3-induced Jurkat cell death by O-glycans on
CD45
We next examined if galectin-3-induced Jurkat cell death was
regulated by O-glycans on CD45. CD45 has several splicing iso-
forms. CD45RABC (the largest isoform) is heavily O-glycosylated
and N-glycosylated, whereas CD45RO (the smallest isoform) is only
N-glycosylated (Fig. 2A). In order to investigate the roles of
CD45RABC or CD45RO in galectin-3-induced apoptosis of JE6-1
cells, CD45RABC cDNA or CD45RO cDNA was transfected into
CD45 J45.01 cells. In contrast to that in empty vector transfectant
(mock control), RT-PCR and Western blotting showed the expres-
sion of CD45RABC or CD45RO in the respective transfected J45.01
cells (Fig. 2B and C). Flow cytometric analysis exhibited CD45RO
or CD45RABC expression on CD45RO-J45.01 or CD45RABC-J45.01
cells, leading to an expression level of CD45 on these cells similar
to that of JE6-1 cells (Fig. 2D). Fig. 2E showed no difference of
expression of other receptors for galectin-3 (CD43, CD29 and
CD71) and the expression of CD3 among mock-J45.01, CD45RO-
J45.01 and CD45RABC-J45.01 cells, indicating that CD45 was rather
speciﬁc for binding and apoptosis induction of the transfectants by
galectin-3 as below. Compared with that to mock-J45.01 cells,
galectin-3 can bind to CD45RO-J45.01 and CD45RABC-J45.01 cells
as that to JE6-1 cells, while this binding can be speciﬁcally inhib-
ited by lactose (Fig. 2F).
All Annexin-V/7-ADD staining, JC-1 and TUNEL assays demon-
strated that galectin-3 could induce apoptosis of CD45RABC-
J45.01 cells, but not of CD45RO-J45.01 cells. Fig. 3A shows aggrega-
tion of both CD45RO-J45.01 and CD45RABC-J45.01 cells induced by
galectin-3. JC-1 assay (Fig. 3B) shows that galectin-3 induced the
collapse of mitochondrial potential in CD45RABC-J45.01 cells
(36.11 ± 3.45% vs 10.34 ± 2.15% compared to untreated control)
whereas the galectin-3 effect was not signiﬁcant in CD45RO-
J45.01 cells (21.80 ± 3.11% vs 20.52 ± 4.34% compared to untreated
control). In Fig. 3C, both CD45RABC-J45.01 and CD45RO-J45.01
cells were BrdU positive after FasL exposure. However, only
CD45RABC-J45.01 but not CD45RO-J45.01 cells were BrdU positive
in the presence of galectin-3. Similarly, Annexin-V/7-ADD staining
showed that the percentage of apoptotic cells was signiﬁcantly in-
creased in CD45RABC-J45.01 cells (40.52 ± 5.55%), but not in
CD45RO-J45.01 cells (8.84 ± 2.68%) and in mock-J45.01 cells
(9.46 ± 2.16%) in the presence of galectin-3 (Fig. 3D). These data
suggest the role played by O-glycans on CD45 in regulation of Jur-
kat cell apoptosis induced by galectin-3. In order to conﬁrm it, O-
glycosylation in cells was inhibited by Benzyl-GalNAc (BG). As
Fig. 1. Role of CD45 in apoptosis induction in JE6-1 cells by galectin-3. (A) Western blotting showed a band with molecular weight about 250 kDa recognized by anti-CD45
antibody in JE6-1 cells but not in J45.01 cells. Actin was used as an internal control. (B) J45.01 or JE6-1 cells were cultured in the absence (Con) or presence (Gal3) of galectin-3
and aggregation of cells was induced by galectin-3 exposure (3 lM). (C) Cells were treated with 3 lM galectin-3 or buffer control for 5.5 h and then stained with PE-Annexin-
V and PerCP-7-AAD. The left panel of ﬂow cytometry analysis shows apoptosis of JE6-1 cells but not in J45.01 cells. The right panel indicates that the percentage of apoptotic
cells is signiﬁcantly larger in JE6-1 cells than in J45.01 cells (⁄P < 0.05). Data shown are the mean ± S.E.M. from three independent experiments. (D) Mitochondrial membrane
potential collapse induced by galectin-3 (3 lM, 5.5 h) was examined by JC-1 dye staining. FasL treated cells (200 ng/ml, 18 h) were used as a positive control. (E) Cells were
incubated with galectin-3 (3 lM, 5.5 h) or FasL as positive control (200 ng/ml, 18 h). Analysis of DNA fragmentation was done by ﬂow cytometry after staining with Br-dUTP
followed by incubation with FITC-labeled anti-BrdU mAb. Dot plots and histograms are representative of three similar experiments.
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treated CD45RABC-J45.01 cells (8.17 ± 2.38%). Together, these data
demonstrated that galectin-3-induced Jurkat cell death was regu-
lated by O-glycans on CD45.
3.3. Effect of site-directed removal of N-glycosylation on galectin-3
binding and galectin-3-induced apoptosis of CD45RO-J45.01 cells
The analysis of the CD45RO sequence suggested eleven
potential sites for N-linked glycosylation (Fig. 4A). To investigate
the possible role of each N-glycosylation site in CD45RO on
galectin-3 binding and induction of apoptosis, eleven CD45ROrecombinants with asparagine (N) to glutamine (Q) mutations
(at individual N-glycosylation sites) were constructed and trans-
fected into J45.01 cells. CD45RO transfectants with N to Q muta-
tions at each N-glycosylation site were ampliﬁed by RT-PCR
(Fig. 4B) and the DNA sequence demonstrated modiﬁcation of
the target site in the sequences. Flow cytometric analysis
showed that expression of CD45 on cells, transfected with an
individual CD45RO mutant, was detected by anti-CD45RO anti-
body (Fig. 4C).
Measurement of binding of galectin-3 to the CD45RO mutant
was performed by ﬂow cytometry and binding was determined
by the mean ﬂuorescence intensity (MFI). The N174Q mutant
Fig. 2. Construction of CD45RO-J45.01 and CD45RABC-J45.01 cells and expression of galectin-3 receptors on the cells. (A) Schematic ﬁgure of CD45RABC isoform and CD45RO
isoform. Compared to CD45RO, CD45RABC has all three alternatively spliced domain denoted A, B and C, which have heavily O-glycosylation. (B) CD45 expression was
analyzed by RT-PCR. J45.01 cells were transfected with empty vector (mock control), CD45RO or CD45RABC. Total RNA was extracted followed by reverse transcription. PCR
ampliﬁed bands were performed using the same CD45 upstream and downstream primers. (C) Western blotting analysis for CD45RO and CD45RABC. 1  107 J45.01 cells
stably expressing mock, CD45RO or CD45RABC were lysed and the lysates were boiled in loading buffer. Then the supernatants were run 6% SDS–PAGE and transferred onto
nitrocellulose membrane. CD45 was detected by rabbit anti-CD45 mAb followed by HRP-labeled goat anti-rabbit polyclonal antibody. (D) Flow cytometry analysis for
expression of CD45 by anti-CD45 antibody on the JE6-1 cells and J45.01 cells transfected with mock, CD45RO or CD45RABC. (E) Polychromatic ﬂow cytometry was performed
to examine CD3, CD29, CD43 or CD71 expression on mock-, CD45RO- and CD45RABC-J45.01 cells stained with PerCP-CD3, PE-CD29, APC-CD43 and FITC-CD71 mAb. (F) Cells
were incubated with 180 nM galectin-3 in the presence or absence of 0.1 M b-lactose. After washing, the cells were then stained with PE-labeled mouse anti-human galectin-
3 antibody for 30 min on ice. Galectin-3 binding to mock-, CD45RO-, CD45RABC-J45.01 cells and JE6-1 cells were examined by ﬂow cytometry. Histograms are representative
of three similar experiments.
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mutant was increased, in terms of galectin-3 binding. However,
galectin-3 binding to N36Q, N71Q, N99Q, N109Q, N115Q, N217Q,
N258Q, N307Q or N368Q mutants was decreased (Fig. 4D).Quantitative data showed that galectin-3-binding to N327Q mu-
tant was enhanced (approximately twofold) whereas in N36Q or
N217Q mutants the galectin-3 binding was largely suppressed
(approximately 0.4-fold). Apoptosis induction by galectin-3 was
Fig. 3. Regulation of galectin-3-induced apoptosis of Jurkat cells by O-glycans on CD45. (A) Aggregation of both CD45RO-J45.01 and CD45RABC-J45.01 cells induced by
galectin-3. Cell apoptosis induced by galectin-3 (3 lM, 5.5 h) was examined by evaluation of mitochondrial membrane potential with JC-1 dye (B), or by Br-dUTP followed by
incubation with FITC-labeled anti-BrdU mAb (C). FasL treatment (200 ng/ml, 18 h) was used as a positive control. (D) CD45RO- or CD45RABC-transfected J45.01 cells were
treated with 3 lM galectin-3 for 5.5 h and subjected to Annexin-V/7-AAD binding assay by ﬂow cytometry. CD45RABC-J45.01 cells were pretreated with O-glycosylation
inhibitor (1 mM, Benzyl-GalNAc, BG) for 24 h before treatment with galectin-3. The percentage of apoptotic cells (right panel) induced by galectin-3 was signiﬁcantly larger in
CD45RABC-J45.01 cells than in mock-J45.01 cells, CD45RO-J45.01 cells and BG-treated CD45RABC-J45.01 cells (⁄P < 0.05). Gal3, BG and Con represent galectin-3, Benzyl-
GalNAc and control, respectively. Dot plots and histograms are representative of three similar experiments. Data shown are the mean ± S.E.M. from three independent
experiments.
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Fig. 5A showed the effect of the removal of the N-glycosylation site
on apoptosis induced by galectin-3. Interestingly, all mutations did
not modify the apoptosis rate of the control cells. However, the
enhancement of apoptosis induction was detected in N36Q
(34.14 ± 2.44% vs 5.25 ± 3.08% compared to WT-CD45RO) and
N109Q (19.45 ± 2.06%) mutants whereas no apoptosis was de-
tected in all other mutants showing concomitantly a decrease ofgalectin-3 binding (Fig. 5B). These data demonstrated that site-
speciﬁc removal of N-glycosylation affected galectin-3 binding
and galectin-3-induced apoptosis in CD45RO-J45.01 cells.
4. Discussion
Galectin-3, a member of a family of b-galactoside-binding ani-
mal lectins, is expressed in a variety of tissues and cell types and
Fig. 4. Effect of the site-directed removal of N-glycosylation on galectin-3 binding to CD45RO-J45.01 cells. (A) DNA sequence showed eleven potential N-glycosylation sites in
CD45RO cDNA. (B) Examination of CD45 expression in transfectants with mock, wild-type (WT) and eleven mutated CD45RO was used by RT-PCR using the same CD45
upstream and downstream primers. WT-CD45RO was shown as positive control and non-transfected J45.01 cells, empty vector (mock) transfectant and H2O were used as
negative control. (C) All transfected CD45RO cells with removal of each N-glycosylation site show CD45 expression on cell surface observed by anti-CD45 antibody staining.
Empty vector (mock) transfectant was used as negative control. (D) Cells were incubated with 180 nM galectin-3 followed by staining with PE-labeled mouse anti-human
galectin-3 antibody. Galectin-3 binding to CD45RO and its mutants expressed in stably transfected J45.01 cells was assayed by ﬂow cytometry. J45.01 cells stably expressed
mock (gray line), WT-CD45RO (ﬁlled) and CD45RO mutants (black line). Quantitative analysis of galectin-3 binding to CD45RO and its mutants was represented as the ratios
of MFI-galectin-3 (staining with PE-labeled anti-galectin-3 mAb) to MFI-CD45RO (staining with PE-labeled anti-CD45RO mAb). MFI represents mean ﬂuorescence intensity.
Data shown are the mean ± S.E.M. from three independent experiments. (⁄P < 0.05 compared to WT).
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types and proliferative states of those cells, a signiﬁcant amount
of the lectin can also be detected in the nucleus, on the cell surface,
or in the extracellular environment [5,8,21,22]. Galectin-3 regu-
lates cell death from both outside and inside the cells [9,23].
Moreover, galectin-3 is the only family member with both pro-
and anti-apoptosis activity [24]. At the intracellular level, cytoplas-
mic galectin-3 antagonizes apoptosis by interacting with the outer
mitochondrial membrane to maintain membrane integrity and
antagonize the release of cytochrome C [23,25,26]. In contrast,
extracellular galectin-3 directly induces cell death by binding cell
surface receptors [27]. CD45 is one such receptor [9,16] that has
been shown to bind another lectin, galectin-1 [11,16]. It has been
reported that galectin-1 recognizes and binds both N-glycans and
O-glycans on CD45 leading to T lymphocyte cell death [11].
In the study of receptors bound by galectin-3 which induced
apoptosis of Jurkat cells, Stillman et al. found that transfection with
murineCD45RABCwas able to restore susceptibility of CD45 J45.01
cells to galectin-3-induced apoptosis [9]. These data strongly dem-
onstrated the involvement of CD45 in galectin-3-induced apoptosis
of Jurkat cells. However, the existence of sequence divergences be-
tween murine and human CD45RABC leading to differences in pro-
tein glycosylation [28], increased the possibility that human
CD45RABC transfection might not have the same effect on restora-
tion of J45.01 cell susceptibility to apoptosis induced by galectin-3.
Although the CD45 is a heavily glycosylated protein, the signif-
icance of its glycosylation in galectin-3-induced apoptosis remainsunclear. Clark et al. reported that galectin-3 could bind to CD45 on
diffuse large B-cell lymphoma cells to regulate the susceptibility to
cell death modiﬁed by C2GnT-1 glycosyltransferase [18]. In present
work, regulation of galectin-3-induced cell death was investigated
in various transfectants with different CD45 isoforms or CD45 mu-
tants. Firstly, we found that galectin-3 could induce the apoptosis
of CD45+ JE6-1 cells, but not CD45 JE6-1 (J45.01) cells, suggesting
the key role of CD45 in regulation of galectin-3-induced death of
Jurkat cells. In order to examine if CD45 was speciﬁc or not for
galelctin-3-induced apoptosis of Jurkat cells, other galectin-3
receptors such as CD43, CD29 and CD71 was detected on mock-
J45.01, CD45RO-J45.01 and CD45RABC-J45.01 cells. For avoiding
involvement of T cell receptor TCR-CD3 in the apoptosis induction,
CD3 on cell surface was also assayed. No difference for expression
level of all these markers was observed among the transfectants,
indicating that galectin-3-induced apoptosis of Jurkat cells is regu-
lated by CD45 but not other receptors.
Next, we investigated roles played by the O-glycans and/or N-
glycans in CD45 molecule in the regulation of galectin-3-induced
death. J45.01 cells expressed with CD45RABC containing both O-
glycans and N-glycans or CD45RO containing N-glycans only were
constructed. Galectin-3-induced apoptosis was observed in
CD45RABC-J45.01 cells but not in CD45RO-J45.01 cells, implying
the regulation of cell death by O-glycans on CD45. Furthermore,
our results showed that galectin-3-induced apoptosis of
CD45RABC-J45.01 cells could be repressed by BG treatment which
can inhibit O-glycosylation of cells. Therefore, it can be suggested
Fig. 5. Effect of the site-directed removal of N-glycosylation on galectin-3-induced apoptosis of CD45RO-J45.01 cells. (A) J45.01 cells transfected with WT-, N36Q-, N71Q-,
N99Q-, N109Q-, N115Q-, N174Q-, N217Q-, N258Q-, N307Q-, N327Q- or N368Q-CD45RO were treated with 3 lM galectin-3 for 5.5 h and apoptosis was measured by PE-
labeled Annexin-V and PerCP-7-AAD binding assay. Dot plots are representative of three similar experiments. Con represents control untreated with galectin-3. (B) The
percentage of apoptotic cells was determined as ((percent Annexin-V 7-AAD cells in control-treated sample) – (percent Annexin-V 7-AAD cells in galectin-3-treated
sample))/(percent Annexin-V 7-AAD cells in control-treated sample). Data shown are the mean ± S.E.M. from three independent experiments. (⁄P < 0.05 compared to WT).
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induced apoptosis of Jurkat cells. It was reported that expression of
different CD45 isoforms differs between T-cell populations,
depending on activation status [28]. Naive T cells express large
CD45RABC isoform, whereas activated and memory T cells expressCD45RO. Thus, naive T cells might be more susceptible to cell death
induced by galectin-3 than activated and memory T cells.
Since CD45RO is heavily N-glycosylated with eleven potential
N-linked glycosylation sites, a question concerning the role of N-
glycans in CD45 cell death induced by galectin-3 was considered.
3994 J. Xue et al. / FEBS Letters 587 (2013) 3986–3994The effect of individual N-glycan on glycoprotein function can be
studied by site-directed mutagenesis of N-glycosylation. For exam-
ple, our previous study demonstrated that deglycosylation at the
N58 site inﬂuenced FcaR binding to IgA [20]. Lige et al. analyzed
the role of three N-linked complex glycans on cationic peroxidase
(cPrx) of peanut by site-directed replacement with Q at three gly-
cosylation sites. These were N60, N144, and N185 individually.
They found that while all three glycosylation sites appeared to
inﬂuence the folding of the protein, the depletion of the glycans
at N60 and N144 modiﬁed the catalytic ability of the cPrx protein
and the glycans at N185 was also important for thermostability
[29]. Sato et al. reported that an N-glycosylation site on the b-pro-
peller domain of the integrin a5 subunit played key roles in both
its function and site-speciﬁc modiﬁcation by b1,4-N-acetylglucos-
aminyltransferase III [30]. Their ﬁnding strongly suggested that
N-glycosylation of site-4 on the a5 subunit was the most impor-
tant site for its biological functions.
In our study, we found that site-speciﬁc removal of N-glycans
affected galectin-3 binding and galectin-3-induced apoptosis of
the mutated CD45RO-J45.01 cells. However, the consequence of re-
moval of the N-glycosylation site in CD45RO on galectin-3 binding
and induction of apoptosis was not equivalent for the eleven mu-
tated sites. More precisely, the N-glycosylation at N327 seemed
to be of importance for galectin-3 binding to CD45, while it was
not involved in apoptosis induction. In contrast, the removal of gly-
cosylation at the N36 and N109 site not only reduced galectin-3
binding to CD45 but surprisingly also led to an increase in the cel-
lular apoptosis rate. Thus, the N-glycans at N36 or N109 position
are of importance in triggering cell death induced by galectin-3,
suggesting that site-speciﬁc N-glycans in CD45 may hamper the
galectin-3-induced apoptosis cascade. Moreover, the lack of apop-
tosis in mutants cultured in control conditions demonstrated the
speciﬁcity of galectin-3 in inducing apoptosis in these cells.
In summary, our study conﬁrms for the ﬁrst time that O-glyco-
sylation in CD45 receptors regulates galectin-3-induced apoptosis
in JE6-1 cells. Although J45.01 cells expressed with CD45RO were
not susceptible to cell death induced by galectin-3, the site-direc-
ted removal of N-glycosylation affected binding and apoptosis in-
duced by galectin-3 in CD45RO-J45.01 cells. This clearly indicates
the important role played by N-glycans on CD45 in the regulation
of galectin-3-induced CD45RO-J45.01 cell death. Finally, our study
demonstrates that galectin-3-induced JE6-1 cell death is speciﬁ-
cally regulated by both O-glycans and N-glycans presence on
CD45. Since galectin-3 has been shown to be important in the reg-
ulation of biological activities in cells, CD45 has been shown to be a
target candidate for new therapies of diseases such as tumor and
inﬂammatory diseases [31,32].
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